SCHEMBL365736

SCHEMBL365736

CCc1cc(O)ccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.52
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
HSD17B3 P37058 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TTR P02766 1/20 0.40
CAMK2A Q9UQM7 1/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
KMT2A Q03164 1/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
TYR P14679 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19025083 0.83 HSD17B10 (0.48) HSD17B10CA12CA1CA2CA7
SCHEMBL1607208 0.82 HSD17B10 (0.52) HSD17B10CA12CA1CA2CA7
SCHEMBL8738071 0.81 HSD17B10 (0.56) HSD17B10CA12CA1CA2CA7
SCHEMBL875816 0.79 TYR (0.61) HSD17B10CA12CA1CA2CA7
SCHEMBL19289759 0.79 HSD17B10 (0.45) HSD17B10CA12CA1CA2CA7
Benzene SCHEMBL631929 0.79 HSD17B10 (0.45) HSD17B10CA12CA1CA2CA7
Tetrabuthylammonium SCHEMBL29130205 0.79 TYR (0.39) HSD17B10KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6131843 0.79 HSD17B10 (0.54) HSD17B10CA12CA1CA2CA7
SCHEMBL696050 0.79 HSD17B10 (0.54) HSD17B10CA12CA1CA2CA7
SCHEMBL1724358 0.78 TYR (0.48) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119326738-A Application of 4-chloro-3-ethylphenol in preparation of medicines for preventing or treating ulcerative colitis and sepsis 青岛大学 2025-01-21 CN claimed
CN-118169963-A Fluorine-free positive photosensitive polyimide resin composition 万华化学集团股份有限公司 2024-06-11 CN claimed
CN-113712945-B Application of 4-chloro-3-ethylphenol in preparation of tumor chemotherapy drug sensitizer and anti-tumor composition 中国人民解放军陆军军医大学第二附属医院 2022-08-02 CN claimed
CN-113712945-A Application of 4-chloro-3-ethylphenol in preparation of tumor chemotherapy drug sensitizer and anti-tumor composition 中国人民解放军陆军军医大学第二附属医院 2021-11-30 CN claimed
US-20180311207-A1 Novel Methods of Treating Hearing Loss THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-11-01 US claimed
EP-3368037-A1 NOVEL METHODS OF TREATING HEARING LOSS The Regents of The University of California (US) 2018-09-05 EP claimed
US-10035033-B2 Fire extinguishing composition comprising alcohol phenol compound and derivative thereof XI'AN WESTPEACE FIRE TECHNOLOGY CO., LTD. (CN) 2018-07-31 US claimed
WO-2017074830-A1 NOVEL METHODS OF TREATING HEARING LOSS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-05-04 WO claimed
EP-3095487-A1 FIRE EXTINGUISHING COMPOSITION COMPRISING ALDOKETONES COMPOUND Xi'an J&R Fire Fighting Equipment Co., Ltd. (CN) 2016-11-23 EP claimed
EP-3095486-A2 FIRE EXTINGUISHING COMPOSITION COMPRISING ALCOHOL PHENOL COMPOUND AND DERIVATIVE THEREOF Xi'an J&R Fire Fighting Equipment Co., Ltd. (CN) 2016-11-23 EP claimed
WO-2001068605-A1 POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-09-20 WO claimed
US-20010018446-A1 Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity G.D. SEARLE & CO. (US) 2001-08-30 US claimed
EP-1115695-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
EP-1115693-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
EP-1115694-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
WO-2000018724-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
WO-2000018723-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
WO-2000018721-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
WO-1998030900-A2 SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA KLAUS TRIER APS (DK) 1998-07-16 WO claimed
US-5136109-A PROCESS FOR PREPARING 2,4-DICHLORO-3-ALKYL-6-NITROPHENOLS TAOKA CHEMICAL COMPANY, LTD. (JP) 1992-08-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018446-A1 Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity CETP, DBI, MTTP HSD17B10 422/4885CA12 4852/4885CA1 4814/4885
US-20180311207-A1 Novel Methods of Treating Hearing Loss ATP2A1, ATP2A2, ATP2A3 HSD17B10 3518/4885CA12 2974/4885CA1 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.